Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ELIZABETH ANN MITTENDORF and JENNIFER LITTON.
ELIZABETH ANN MITTENDORF
Connection Strength
4.371
JENNIFER LITTON
  1. PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects - A Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2024 Aug 13.
    View in: PubMed
    Score: 0.246
  2. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.
    View in: PubMed
    Score: 0.239
  3. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.224
  4. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676.
    View in: PubMed
    Score: 0.215
  5. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
    View in: PubMed
    Score: 0.201
  6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.199
  7. Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2515-2523.
    View in: PubMed
    Score: 0.180
  8. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.174
  9. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. 2019 Aug 01; 5(8):1205-1214.
    View in: PubMed
    Score: 0.173
  10. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol. 2018 07; 192:6-13.
    View in: PubMed
    Score: 0.158
  11. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 2017; 3:49.
    View in: PubMed
    Score: 0.154
  12. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+?T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol. 2017 Aug; 24(8):2161-2167.
    View in: PubMed
    Score: 0.147
  13. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016 Oct 04; 7(40):66192-66201.
    View in: PubMed
    Score: 0.142
  14. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016 07; 27(7):1241-8.
    View in: PubMed
    Score: 0.137
  15. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol. 2016 Mar; 23(3):749-56.
    View in: PubMed
    Score: 0.133
  16. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
    View in: PubMed
    Score: 0.118
  17. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
    View in: PubMed
    Score: 0.113
  18. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist. 2013; 18(4):369-76.
    View in: PubMed
    Score: 0.112
  19. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
    View in: PubMed
    Score: 0.112
  20. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.
    View in: PubMed
    Score: 0.105
  21. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.100
  22. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82.
    View in: PubMed
    Score: 0.095
  23. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer. 2010 Feb; 10(1):52-8.
    View in: PubMed
    Score: 0.090
  24. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.062
  25. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 Mar; 8:e2300124.
    View in: PubMed
    Score: 0.059
  26. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  27. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.057
  28. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.053
  29. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.052
  30. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220.
    View in: PubMed
    Score: 0.052
  31. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021 04; 225:108679.
    View in: PubMed
    Score: 0.048
  32. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun; 181(2):391-401.
    View in: PubMed
    Score: 0.046
  33. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019; 5:34.
    View in: PubMed
    Score: 0.044
  34. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7.
    View in: PubMed
    Score: 0.041
  35. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design. Clin Immunol. 2018 10; 195:28-35.
    View in: PubMed
    Score: 0.040
  36. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
    View in: PubMed
    Score: 0.040
  37. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer. 2015 Apr; 15(2):153-60.
    View in: PubMed
    Score: 0.031
  38. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.026
  39. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011 Oct; 18(11):3164-73.
    View in: PubMed
    Score: 0.025
  40. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011 Oct; 11(5):325-31.
    View in: PubMed
    Score: 0.025
  41. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011 May; 127(5):1763-1772.
    View in: PubMed
    Score: 0.024
  42. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.